

## **ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!**

<https://marketpublishers.com/r/E214FAA0410EN.html>

Date: April 2013

Pages: 8

Price: US\$ 140.00 (Single User License)

ID: E214FAA0410EN

### **Abstracts**

Gilead entered the HCV race with the acquisition of Pharmasset in 2011 and ABBV through its alliance with Enanta (ENTA) in 2006. Gilead's Sofosbuvir (PhIII, PMI) in combination with RBV and GS-5885 (PhIII, NS5A inhibitor) is all set to enter the market by 2014 but ENTA/ABBV's DAAs (ABT-450, PI/r + ABT-333, PMI + ABT-267, NS5AI) will not be too far behind. In PhIIb AVIATOR study, tirade of DAAs demonstrated SVR12 (ITT) of 97.5%, and 93.3% in treatment-naïve pts and null responder HCV GT1 pts respectively. The total INF-free HCV market is expected to grow beyond \$10b and as a second entrant ABT-450 combo could achieve.....For more detail, please read our initiation report released on 17th April, 2013 on ENTA titled "Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!"

## I would like to order

Product name: ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!

Product link: <https://marketpublishers.com/r/E214FAA0410EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E214FAA0410EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970